BibTex RIS Cite

Rhabdomyolysis Related Statine and Fibrate Combination Theraphy: A Single Case

Year 2013, , 171 - 172, 01.05.2013

Ahsen Zeyrek İşçi Gülali Aktaş Sevim Karaçay Haluk Şavlı

https://doi.org/10.5505/abantmedj.2013.38039

References

  • A. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med 2002; 137:617.
  • Sathasivam S, Lecky B Statin induced myo- pathy.BMJ. 2008 Nov 6;337:2286
  • Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012 Jun;23(4):317-24
  • Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; Ameri- can College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Sta- tins.Stroke. 2002 Sep;33(9):2337-41
  • Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14
  • Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P Meta- analysis of drug-induced adverse events associated with intensive-dose statin the- rapy Clin Ther. 2007 Feb;29(2):253-60
  • Antons KA, Williams CD, Baker SK, Phillips PS.Clinical perspectives of statin-induced rhabdomyolysis Am J Med. 2006 May;119(5):400-9
  • Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A. Incidence of hospi- talized rhabdomyolysis with statin and fib- rate use in an insured US population. Ann Pharmacother. 2011 Oct;45(10):1230-9.
  • Farnier M, Marcereuil D, De Niet S, Ducobu J, Steinmetz A, Retterstİl K, Bryniarski L, Császár A, Vanderbist F. Safety of a fixed- dose te/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials. Clin Drug Investig. 2012 Apr 1;32(4):281-91
  • Davidson MH, Armani A, McKenney JM, Ja- cobson TA Safety considerations with fibra- te therapy Am J Cardiol. 2007 Mar 19;99(6A):3C-18C
  • Baer AN, Wortmann RL Myotoxicity associ- ated with lipid-lowering drugs Curr Opin Rheumatol. 2007 Jan;19(1):67-73
  • Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur Dec;65(12):1169-74 2009

Statin ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomyoliz: Bir Olgu Nedeniyle

Year 2013, , 171 - 172, 01.05.2013

Ahsen Zeyrek İşçi Gülali Aktaş Sevim Karaçay Haluk Şavlı

https://doi.org/10.5505/abantmedj.2013.38039

References

  • A. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med 2002; 137:617.
  • Sathasivam S, Lecky B Statin induced myo- pathy.BMJ. 2008 Nov 6;337:2286
  • Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012 Jun;23(4):317-24
  • Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; Ameri- can College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Sta- tins.Stroke. 2002 Sep;33(9):2337-41
  • Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14
  • Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P Meta- analysis of drug-induced adverse events associated with intensive-dose statin the- rapy Clin Ther. 2007 Feb;29(2):253-60
  • Antons KA, Williams CD, Baker SK, Phillips PS.Clinical perspectives of statin-induced rhabdomyolysis Am J Med. 2006 May;119(5):400-9
  • Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A. Incidence of hospi- talized rhabdomyolysis with statin and fib- rate use in an insured US population. Ann Pharmacother. 2011 Oct;45(10):1230-9.
  • Farnier M, Marcereuil D, De Niet S, Ducobu J, Steinmetz A, Retterstİl K, Bryniarski L, Császár A, Vanderbist F. Safety of a fixed- dose te/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials. Clin Drug Investig. 2012 Apr 1;32(4):281-91
  • Davidson MH, Armani A, McKenney JM, Ja- cobson TA Safety considerations with fibra- te therapy Am J Cardiol. 2007 Mar 19;99(6A):3C-18C
  • Baer AN, Wortmann RL Myotoxicity associ- ated with lipid-lowering drugs Curr Opin Rheumatol. 2007 Jan;19(1):67-73
  • Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur Dec;65(12):1169-74 2009
There are 12 citations in total.

Details

Primary Language Turkish
Journal Section Letter to Editor
Authors

Ahsen Zeyrek İşçi This is me

Gülali Aktaş This is me

Sevim Karaçay This is me

Haluk Şavlı This is me

Publication Date May 1, 2013
Published in Issue Year 2013

Cite

APA İşçi, A. Z., Aktaş, G., Karaçay, S., Şavlı, H. (2013). Statin ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomyoliz: Bir Olgu Nedeniyle. Abant Medical Journal, 2(2), 171-172. https://doi.org/10.5505/abantmedj.2013.38039
AMA İşçi AZ, Aktaş G, Karaçay S, Şavlı H. Statin ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomyoliz: Bir Olgu Nedeniyle. Abant Med J. May 2013;2(2):171-172. doi:10.5505/abantmedj.2013.38039
Chicago İşçi, Ahsen Zeyrek, Gülali Aktaş, Sevim Karaçay, and Haluk Şavlı. “Statin Ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomyoliz: Bir Olgu Nedeniyle”. Abant Medical Journal 2, no. 2 (May 2013): 171-72. https://doi.org/10.5505/abantmedj.2013.38039.
EndNote İşçi AZ, Aktaş G, Karaçay S, Şavlı H (May 1, 2013) Statin ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomyoliz: Bir Olgu Nedeniyle. Abant Medical Journal 2 2 171–172.
IEEE A. Z. İşçi, G. Aktaş, S. Karaçay, and H. Şavlı, “Statin ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomyoliz: Bir Olgu Nedeniyle”, Abant Med J, vol. 2, no. 2, pp. 171–172, 2013, doi: 10.5505/abantmedj.2013.38039.
ISNAD İşçi, Ahsen Zeyrek et al. “Statin Ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomyoliz: Bir Olgu Nedeniyle”. Abant Medical Journal 2/2 (May 2013), 171-172. https://doi.org/10.5505/abantmedj.2013.38039.
JAMA İşçi AZ, Aktaş G, Karaçay S, Şavlı H. Statin ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomyoliz: Bir Olgu Nedeniyle. Abant Med J. 2013;2:171–172.
MLA İşçi, Ahsen Zeyrek et al. “Statin Ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomyoliz: Bir Olgu Nedeniyle”. Abant Medical Journal, vol. 2, no. 2, 2013, pp. 171-2, doi:10.5505/abantmedj.2013.38039.
Vancouver İşçi AZ, Aktaş G, Karaçay S, Şavlı H. Statin ve Fenofibrat Birlikte Kullanımına Bağlı Rabdomyoliz: Bir Olgu Nedeniyle. Abant Med J. 2013;2(2):171-2.